Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
ERK5, a MAPK type protein kinase, mediates growth factor stimulated cell proliferation and muscle cell differentiation. ERK5 differs from other MAP kinases in that it contains a unique loop-12 region within the protein kinase domain which is followed by an extensive C-terminal tail with sequences indicating that it may be targeted to the cytoskeleton. ERK5 is phosphorylated and activated by MEK5 in response to osmotic shock, growth factors and oxidant stress.
Formalin-fixed and paraffin-embedded human kidney carcinoma tissue reacted with ERK5 Antibody , which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated.
Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma.
Western blot of anti-ERK5 C-term antibody in K562 cell line lysates (35 ug/lane). ERK5 (arrow) was detected using the purified antibody.
Requested From: United States
Date Requested: 1/22/2017